Insulin Savings for Patients Act

United States117th CongressHR-6757House of Representatives
Updated: Feb 21, 2022

Summary

Insulin Savings for Patients Act This bill requires 100% of negotiated price concessions for covered insulin products under the Medicare prescription drug benefit to be reflected at the point of sale by 2024. The Government Accountability Office must annually report on the effects of the bill's implementation, including with respect to insulin prices.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Introduced in House

  2. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    House of Representatives

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.